OBJECTIVE: To examine if there is a significant difference in survival between elderly (>50 years) and nonelderly adult patients receiving combination antiretroviral therapy in Uganda between 2004 and 2010. DESIGN: Prospective observational study. METHODS: Patients 18-49 years of age (nonelderly) and 50 years of age and older enrolled in the AIDS Support Organization Uganda HIV/AIDS national programme were assessed for time to all-cause mortality. We applied a Weibull multivariable regression. RESULTS: Among the 22 087 patients eligible for analyses, 19 657 (89.0%) were aged between 18 and 49 years and 2430 (11.0%) were aged 50 years or older. These populations differed in terms of the distributions of sex, baseline CD4 cell count and death. The age group 40-44 displayed the lowest crude mortality rate [31.4 deaths per 1000 person-years; 95% confidence interval (CI) 28.1, 34.7) and the age group 60-64 displayed the highest crude mortality rate (58.9 deaths per 1000 person-years; 95% CI 42.2, 75.5). Kaplan-Meier survival estimates indicated that nonelderly patients had better survival than elderly patients (P < 0.001). Adjusted Weibull analysis indicated that elderly age status was importantly associated (adjusted hazard ratio 1.23, 95% CI 1.08-1.42) with mortality, when controlling for sex, baseline CD4 cell count and year of therapy initiation. CONCLUSION: As antiretroviral treatment cohorts mature, the proportion of patients who are elderly will inevitably increase. Elderly patients may require focused clinical care that extends beyond HIV treatment.
OBJECTIVE: To examine if there is a significant difference in survival between elderly (>50 years) and nonelderly adult patients receiving combination antiretroviral therapy in Uganda between 2004 and 2010. DESIGN: Prospective observational study. METHODS:Patients 18-49 years of age (nonelderly) and 50 years of age and older enrolled in the AIDS Support Organization Uganda HIV/AIDS national programme were assessed for time to all-cause mortality. We applied a Weibull multivariable regression. RESULTS: Among the 22 087 patients eligible for analyses, 19 657 (89.0%) were aged between 18 and 49 years and 2430 (11.0%) were aged 50 years or older. These populations differed in terms of the distributions of sex, baseline CD4 cell count and death. The age group 40-44 displayed the lowest crude mortality rate [31.4 deaths per 1000 person-years; 95% confidence interval (CI) 28.1, 34.7) and the age group 60-64 displayed the highest crude mortality rate (58.9 deaths per 1000 person-years; 95% CI 42.2, 75.5). Kaplan-Meier survival estimates indicated that nonelderly patients had better survival than elderly patients (P < 0.001). Adjusted Weibull analysis indicated that elderly age status was importantly associated (adjusted hazard ratio 1.23, 95% CI 1.08-1.42) with mortality, when controlling for sex, baseline CD4 cell count and year of therapy initiation. CONCLUSION: As antiretroviral treatment cohorts mature, the proportion of patients who are elderly will inevitably increase. Elderly patients may require focused clinical care that extends beyond HIV treatment.
Authors: Michael J Vinikoor; Jessica Joseph; Jonas Mwale; Melissa A Marx; Fastone M Goma; Lloyd B Mulenga; Jeffrey S A Stringer; Joseph J Eron; Benjamin H Chi Journal: AIDS Res Hum Retroviruses Date: 2014-08-05 Impact factor: 2.205
Authors: Morna Cornell; Leigh F Johnson; Michael Schomaker; Frank Tanser; Mhairi Maskew; Robin Wood; Hans Prozesky; Janet Giddy; Kathryn Stinson; Matthias Egger; Andrew Boulle; Landon Myer Journal: Lancet HIV Date: 2015-08-04 Impact factor: 12.767
Authors: J M Foley; A L Gooding; A D Thames; M L Ettenhofer; M S Kim; S A Castellon; T D Marcotte; J R Sadek; R K Heaton; W G van Gorp; C H Hinkin Journal: Am J Alzheimers Dis Other Demen Date: 2013-01-11 Impact factor: 2.035
Authors: Ekwaro A Obuku; Sujal M Parikh; Victoria Nankabirwa; Nelson I Kakande; David K Mafigiri; Harriet Mayanja-Kizza; Cissy M Kityo; Peter N Mugyenyi; Robert A Salata Journal: PLoS One Date: 2013-02-28 Impact factor: 3.240
Authors: Sujal M Parikh; Ekwaro A Obuku; Sarah A Walker; Aggrey S Semeere; Brandon J Auerbach; James G Hakim; Harriet Mayanja-Kizza; Peter N Mugyenyi; Robert A Salata; Cissy M Kityo Journal: PLoS One Date: 2013-10-02 Impact factor: 3.240